Side effects of antidepressants, the second most prescribed drug in America, weaken bone growth, a crucial factor for implant success

Antidepressants linked to tooth implant failure, new study finds

 

BUFFALO, N.Y. (March 8, 2016) – Antidepressants, commonly used to treat anxiety, pain and other disorders, may play a role in dental implant failure, according to a new pilot study by University at Buffalo researchers. The research found that the use of antidepressants increased the odds of implant failure by four times. Each year of antidepressant use doubled the odds of failure. While these drugs are often used to manage mood and emotions, a side effect decreases the regulation of bone metabolism, which is crucial to the healing process.


For an implant to heal properly, new bone must form around it to secure it in place, says Sulochana Gurung, lead investigator and a doctor of dental surgery (DDS) candidate.

 

"Antidepressant medication may relieve depression symptoms and help millions of patients worldwide, however, their benefits must be weighed with the side effects. Patients should cooperate with their physician to reach the right balance," says Latifa Bairam, DDS, MS, an investigator on the study and clinical assistant professor in the Department of Restorative Dentistry in the UB School of Dental Medicine.

 

"Four of the many known side effects that are reported in the literature are a big concern to us as dentists in regard to oral and bone health."

 

Additional side effects of the drug include osteoporosis, a condition in which bones become weak and brittle; akathisia, a disorder characterized by the need to be in constant motion, including the head and jaw; bruxism, or teeth grinding; and dryness of the mouth, all of which affect the implant healing process, says Bairam.

 

The research, "A Pilot Study: Association between Antidepressant Use and Implant Failure," was funded by the Student Research Program through the SDM Dean’s Vision Fund.

 

Gurung will present the findings at the 45th annual American Association for Dental Research conference on March 19. She also presented at the School of Dental Medicine’s 2016 Student Research Day on Feb. 25.

 

She completed the study under the mentorship of Bairam, Sebastiano Andreana, DDS, MS, associate professor and director of implant dentistry, and Mine Tezal, PhD, DDS, clinical assistant professor in the Department of Oral Biology.

 

The research began to take shape after Bairam and Andreana, who have previously studied implant failure, noticed that a growing number of their patients reported use of antidepressant medication.

 

After analyzing data from the medical charts of UB Dental Clinic patients in 2014, the researchers found that of the few patients who experienced implant failures, 33 percent used antidepressants. For patients who did not experience failures, only 11 percent used the drug.

 

"We decided that the dental community and the world should be aware of this, and that triggered the preparation of the research," says Andreana. "The difference between 33 percent and 11 percent is quite remarkable and needs further in-depth analysis."

 

More than one in 10 Americans over the age of 12 use antidepressants, making it the second most prescribed type of drug in the U.S., according to data from the Centers for Disease Control and Prevention (CDC) and IMS Health.

 

And the rate is increasing. Antidepressant use has surged 400 percent between the periods 1988-94 and 2005-08, according to the CDC.

 

The researchers plan to build on the study by retesting their results on a larger scale. For now, they advise those using antidepressants to consult with their physician about the drug’s side effects and alternative methods of managing depression, anxiety or pain.

 

 


University at Buffalo, 08.03.2016 (tB).

MEDICAL NEWS

New guidance to prevent the tragedy of unrecognized esophageal intubation
Overly restrictive salt intake may worsen outcomes for common form…
COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Scientists discover how salt in tumours could help diagnose and…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Kaltplasma bei diabetischem Fußsyndrom wirkt via Wachstumsfaktoren
Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…

ERNÄHRUNG

Gesunde Ernährung: „Nicht das Salz und nicht das Fett verteufeln“
Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
Aktuelle Kongressdaten zum metastasierten Mammakarzinom und kolorektalen Karzinom sowie Neues…
Mehr Lebensqualität für onkologische Patient:innen durch bessere Versorgung: Supportivtherapie, Präzisionsonkologie,…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver

MULTIPLE SKLEROSE

Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…